KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Pacific Biosciences Of California (PACB) over the last 16 years, with Q3 2025 value amounting to $30.6 million.

  • Pacific Biosciences Of California's Receivables - Net rose 419.63% to $30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.6 million, marking a year-over-year increase of 419.63%. This contributed to the annual value of $27.5 million for FY2024, which is 2482.86% down from last year.
  • Pacific Biosciences Of California's Receivables - Net amounted to $30.6 million in Q3 2025, which was up 419.63% from $32.3 million recorded in Q2 2025.
  • In the past 5 years, Pacific Biosciences Of California's Receivables - Net ranged from a high of $36.6 million in Q4 2023 and a low of $12.9 million during Q1 2021
  • Its 5-year average for Receivables - Net is $27.0 million, with a median of $27.9 million in 2022.
  • As far as peak fluctuations go, Pacific Biosciences Of California's Receivables - Net skyrocketed by 11580.66% in 2022, and later crashed by 2482.86% in 2024.
  • Quarter analysis of 5 years shows Pacific Biosciences Of California's Receivables - Net stood at $24.2 million in 2021, then dropped by 22.5% to $18.8 million in 2022, then soared by 94.91% to $36.6 million in 2023, then fell by 24.83% to $27.5 million in 2024, then grew by 11.23% to $30.6 million in 2025.
  • Its last three reported values are $30.6 million in Q3 2025, $32.3 million for Q2 2025, and $31.6 million during Q1 2025.